Jacobs Levy Equity Management
AMRX icon

Jacobs Levy Equity Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Jacobs Levy Equity Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$823K Buy
+47,519
New +$651K ﹤0.01% 742
2024
Q4 		– Sell
-97,379
Closed -$810K – 933
2024
Q3 		$810K Sell
97,379
-189,881
-66% -$1.48M ﹤0.01% 765
2024
Q2 		$1.82M Sell
287,260
-57,988
-17% -$368K 0.01% 620
2024
Q1 		$2.09M Sell
345,248
-54,985
-14% -$310K 0.01% 591
2023
Q4 		$2.43M Buy
400,233
+300,832
+303% +$1.34M 0.01% 572
2023
Q3 		$419K Buy
99,401
+71,975
+262% +$268K ﹤0.01% 835
2023
Q2 		$85K Sell
27,426
-1,953,020
-99% -$4.16M ﹤0.01% 950
2023
Q1 		$2.75M Buy
1,980,446
+278,411
+16% +$554K 0.02% 519
2022
Q4 		$3.39M Buy
1,702,035
+259,725
+18% +$582K 0.02% 462
2022
Q3 		$2.91M Sell
1,442,310
-81,866
-5% -$229K 0.02% 486
2022
Q2 		$4.85M Sell
1,524,176
-63,780
-4% -$231K 0.04% 426
2022
Q1 		$6.62M Sell
1,587,956
-113,101
-7% -$501K 0.04% 369
2021
Q4 		$8.15M Sell
1,701,057
-181,129
-10% -$903K 0.05% 343
2021
Q3 		$10.1M Sell
1,882,186
-217,748
-10% -$1.1M 0.07% 296
2021
Q2 		$10.8M Buy
2,099,934
+436,882
+26% +$2.48M 0.07% 277
2021
Q1 		$11.2M Buy
1,663,052
+948,233
+133% +$5.26M 0.09% 270
2020
Q4 		$3.27M Buy
714,819
+414,546
+138% +$1.84M 0.03% 479
2020
Q3 		$1.17M Buy
300,273
+230,224
+329% +$985K 0.01% 628
2020
Q2 		$333K Sell
70,049
-177,725
-72% -$732K ﹤0.01% 867
2020
Q1 		$862K Buy
+247,774
New +$1.05M 0.01% 661
2019
Q4 		– Sell
-200,600
Closed -$582K – 993
2019
Q3 		$582K Buy
200,600
+165,800
+476% +$579K 0.01% 698
2019
Q2 		$250K Buy
+34,800
New +$356K ﹤0.01% 843

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Jacobs Levy Equity Management's AMRX Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Amneal Pharmaceuticals (AMRX) in Q2 2026: 47,519 shares worth $823K. The stake represents ﹤0.01% of the portfolio and ranks #742 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in AMRX as recently as Q3 2024.

Jacobs Levy Equity Management first reported a position in AMRX in Q2 2019 and has held it in 22 quarters since. The position peaked at $11.2M in Q1 2021. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Jacobs Levy Equity Management held 47,519 shares of Amneal Pharmaceuticals worth $823K as of Q2 2026.
  • Amneal Pharmaceuticals was a new Jacobs Levy Equity Management position in Q2 2026.
  • Amneal Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #742 holding.
  • Jacobs Levy Equity Management first reported a position in Amneal Pharmaceuticals in Q2 2019 and has held it in 22 quarters since.
  • Jacobs Levy Equity Management's Amneal Pharmaceuticals position peaked at $11.2M in Q1 2021.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.